{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"","title":"Why Development-Led CDMOs Will Win","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/6846e583cca944a48e6715d3/1779261176322-0f3fe55d-24e7-4309-90dc-062f010c77d2.jpeg?height=200","description":"

95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes.


How do leading CDMOs move beyond manufacturing to become true development partners? In this episode, Jeffrey Speicher shares how integrated development, technical problem solving and long-term partnerships are shaping growth in outsourced pharma manufacturing.


This week on Making It In Manufacturing, Harry Sloan sat down with Jeffrey Speicher, General Manager Commercial of PLD Pharma, with over 30 years of experience spanning engineering, commercial leadership, contract manufacturing, OTC product development and strategic growth across the pharmaceutical and consumer healthcare sectors.


In this episode, Jeffrey Speicher covers:


- How PLDevelopments evolved from a private label manufacturer into a full CDMO model focused on end-to-end support for customers

- Why in-house development and commercialisation capabilities help accelerate speed to market and reduce manufacturing risk for pharmaceutical products

- The importance of designing formulations around commercial manufacturing equipment from the very beginning of the R&D process

- How product diversification across liquids, tablets, electrolytes, and gummies creates broader manufacturing capabilities within the CDMO market

- Why partnership-led relationships matter for pharmaceutical brands looking for quality, consistency, and long-term manufacturing support in the US market


For anyone operating across CDMO strategy, OTC innovation or outsourced development, this is a thoughtful conversation on what partnership-led manufacturing really looks like. Be sure to check out the full episode for a deeper discussion on leadership, commercial growth and differentiated execution in pharma services.


Follow ARTO


LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Website: https://arto-talent.com/

Youtube: https://www.youtube.com/@artotalent


Jeffrey Speicher

General Manager Commercial at PLD Pharma

LinkedIn: https://www.linkedin.com/in/jeffrey-speicher-826746/


Harry Sloan

CDMO BD Lead at ARTO

LinkedIn: https://www.linkedin.com/in/harry-sloan/


Timestamps:


00:00 Introduction

00:21 Jeffrey Speicher introduction and overview of PL Developments

00:45 The origins of PL Developments and private label manufacturing

01:07 Transitioning into a CDMO-focused business model

01:25 What differentiates PL Developments from traditional CDMOs

01:44 The advantages of broad formulation and manufacturing capabilities

02:26 Why upstream development support improves project success

03:05 Connecting R&D with commercial manufacturing equipment

03:37 Speed to market and reducing commercialisation risk

03:55 Competing through partnership and customer focus

04:29 Balancing speed, efficiency, and scalability in manufacturing

05:09 Developing OTC gummies and expanding manufacturing capabilities

05:28 Designing products around plant strengths

05:40 Eliminating risk during commercial transfer

05:44 Closing remarks


#MakingItInManufacturing #ARTOTalent #CDMO #PharmaceuticalManufacturing #OTCManufacturing #DrugDevelopment #ContractManufacturing #LifeSciences

","author_name":"ARTO Talent"}